Details

Autor(en) / Beteiligte

• Shields, Alan L.
• Lamoureux, Roger E.
• Taylor, Fiona
• Barth, Jay A.
• Mulberg, Andrew E.
• Kessler, Vivian
• Skuban, Nina

Titel

FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument

Ist Teil von

• Quality of life research, 2021-10, Vol.30 (10), p.2983-2994

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Fabry disease is a rare multisystemic disorder caused by functional deficiency of the lysosomal enzyme alpha-galactosidase A. Gastrointestinal (GI) signs and symptoms are among the earliest clinical manifestations in patients with Fabry disease but are often nonspecific, misdiagnosed, and untreated. No instruments have been developed specifically to assess GI signs and symptoms in Fabry disease. The FAB ry disease P atient- R eported O utcome- G astro I ntestinal (FABPRO-GI) was developed to address this unmet need and is intended for use in clinical trials (24-h FABPRO-GI) and real-world settings (7-day FABPRO-GI). Methods Findings from a literature review, expert advisory meetings, and patient concept elicitation interviews (CEIs) were summarized into conceptual models. These conceptual models were used to develop preliminary versions of the 24-h and 7-day FABPRO-GI. Cognitive debriefing interviews (CDIs) were conducted with additional patients to assess content validity, including understandability, relevance, and comprehensiveness of the preliminary versions of the 24-h and 7-day FABPRO-GI. Results Literature review ( n  = 17 articles), expert advisory meetings ( n  = 5), and patient CEIs ( n  = 17) identified mostly overlapping Fabry disease-related GI signs and symptoms, including abdominal cramps, bloating, and diarrhea, and informed development of the preliminary 24-h and 7-day FABPRO-GI. CDIs ( n  = 15) provided evidence of content validity and informed revisions of the 24-h and 7-day FABPRO-GI. Conclusion With evidence of content validity, the 24-h and 7-day FABPRO-GI are the first Fabry disease-specific patient-reported outcomes to assess GI signs and symptoms in patients with Fabry disease with potential for use in clinical trials and real-world settings, respectively.